Replies to post #151903 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

At your given 8+ months over SOC in GBM, it would likely mean it would dominate the market in all solid tumor indications by the end of three years. The pps number would be ridiculously high, and therefore bulls are reluctant to shout out these days until we get some actual data.

[Evaluate]

Mike, you wrote::

Again... Given public/available info, what is the SP potential in a best case scenario over 3 years?

Best case scenario is very difficult to estimate. Perhaps somewhere between $5/share to $100/share. I do not think anyone has a crystal ball at this point that could pinpoint an exact number. How about you ... what number is your guess, based on your own due diligence and research?

[sentiment_stocks]

In three years, once the market factors in what Direct can do, $50 or more per share.

On GBM approval - $9 or $10 (based on a low multiple of 5 and 1 billion shares) - but I think this is a low estimate.

Once the market realizes that DCVax-L can be used for Astroctyomas, Oligodendrogliomas, and Recurrent GBM, as well as other brain cancer tumor types, that share price should increase.

And of course, L can be used for many other types of operable solid tumor types, however I'd think the brain tumor types would want to access L right away. UCLA used DCVax-L on these other brain tumors in their trials.